The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers

British Journal of Cancer

Volumn 107, Issue 12, 2012, Pages 2005-2009

  Iqbal, J ^a   Ragone, A ^b   Lubinski, J ^c   Lynch, H T ^d   Moller, P ^e   Ghadirian, P ^f   Foulkes, W D ^g   Armel, S ^h   Eisen, A ⁱ   Neuhausen, S L ^j   Senter, L ^k   Singer, C F ^l   Ainsworth, P ^m   Kim Sing, C ⁿ   Tung, N ^o   Friedman, E ^a   Llacuachaqui, M ^a   Ping, S ^a   Narod, S A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

ⁱ City of Hope ^*  (United States)

^j THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^k UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^l LONDON REGIONAL CANCER PROGRAM   (Canada)

^m BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁿ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^o TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

BRCA1; BRCA2; incidence; pancreatic cancer; survival

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC RISK; GROUPS BY AGE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PANCREAS CANCER; PEDIGREE; PRIORITY JOURNAL; STANDARDIZED INCIDENCE RATIO; TIME OF DEATH; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; COHORT STUDIES; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 84870802792     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.483     Document Type: Article

References (20)

1. Bartsch DK, Kress R, Sina-Frey M, Grutzmann R, Gerdes B, Pilarsky C et al.(2004) Prevalence of familial pancreatic cancer in Germany. Int J Cancer110: 902-906
2. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB,Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somaticmutations and homozygous deletions of the p16 (MTS1) gene inpancreatic adenocarcinoma. Nat Genet 8: 27-32
3. Canadian Cancer Society (2010) Canadian Cancer Statistics. CanadianCancer Society.
4. TorontoGhiorzo P, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bernard L,Bonelli L, Borgonovo G, Bruno W, De Cian F, Decensi A, Filauro M,Faravelli F, Gozza A, Gargiulo S, Mariette F, Nasti S, Pastorino L,Queirolo P, Savarino V, Varesco L, Scarrà GB. Genoa Pancreatic CancerStudy Group (2012) CDKN2A is the main susceptibility gene in Italianpancreatic cancer families. J Med Genet 49: 164-170
5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010)GLOBOCAN 2008 v1.2 cancer incidence and mortality worldwide: IARCCancerBase No. 10 (Internet). Lyon, France: International Agency forResearch on Cancer; available from http://globocan.iarc.fr
6. Fernandez E, La Vecchia C, D'Avanzo B, Negri E, Franceschi S (1994)Family history and the risk of liver, gallbladder, and pancreatic cancer.Cancer Epidemiol Biomarkers Prev 3: 209-212
7. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E,Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, acandidate tumor suppressor gene at human chromosome 18q21.1.Science 271: 350-353
8. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW,Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, MaitraA, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B,Eshleman JR, Goggins M, Klein AP (2009) Exomic sequencing identifiesPALB2 as a pancreatic cancer susceptibility gene. Science 324: 217
9. Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M (2001) Familialpancreatic cancer. Cancer J 7: 266-273
10. Lal G, Liu G, Schmocker B, Kaurah P, Ozcelik H, Narod SA, Redston M,Gallinger S (2000) Inherited predisposition to pancreatic adenocarcinoma:role of family history and germ-line p16, BRCA1,and BRCA2 mutations. Cancer Res 60: 409-416
11. Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E,D'Adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O'ReillyEM (2011) An emerging entity: pancreatic adenocarcinomaassociated with a known BRCA mutation: clinical descriptors, treatmentimplications, and future directions. Oncologist 16: 1397-1402
12. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C,Carter R, Ghadirian P, Perret C, Moslehi R, Dion F, Faucher MC,Dole K, Karimi S, Foulkes W, Lounis H, Warner E, Goss P, Anderson D,Larsson C, Narod SA, Futreal PA (1996) Mutation analysis of theBRCA2 gene in 49 site-specific breast cancer families. Nat Genet 13:120-122
13. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ,Kern SE (1994) p53 mutations in pancreatic carcinoma and evidence ofcommon involvement of homocopolymer tracts in DNA microdeletions.Cancer Res 54: 3025-3033
14. Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Fan I, Ang J,Li S, Zhang S, Shaw PA, Narod SA (2006) Population BRCA1 and BRCA2mutation frequencies and cancer penetrances: a kin-cohort study inOntario, Canada. J Natl Cancer Inst 98: 1694-1706
15. Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML,Gallinger S, Schwartz AG, Syngal S, Cote ML, Axilbund J, Schulick R,Ali SZ, Eshleman JR, Velculescu VE, Goggins M, Vogelstein B, PapadopoulosN, Hruban RH, Kinzler KW, Klein AP (2011) ATM mutations inpatients with hereditary pancreatic cancer. Cancer Discov 2: 41-46
16. Sato N, Rosty C, Jansen M, Fukushima N, Ueki T, Yeo CJ, Cameron JL,Iacobuzio-Donahue CA, Hruban RH, Goggins M (2001) STK11/LKB1Peutz-Jeghers gene inactivation in intraductal papillary-mucinousneoplasms of the pancreas. Am J Pathol 159: 2017-2022
17. The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2mutation carriers. J Natl Cancer Inst 91: 1310-1316
18. Thompson D, Easton DF, Breast Cancer Linkage Consortium (2002)Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365
19. van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC,Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH,Kern SE (2005) In vivo therapeutic responses contingent on Fanconianemia/BRCA2 status of the tumor. Clin Cancer Res 11: 7508-7515
20. Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP,Buchanan DD, Clendenning M, Giles GG, Winship I, Macrae FA,Goldblatt J, Southey MC, Arnold J, Thibodeau SN, Gunawardena SR,Bapat B, Baron JA, Casey G, Gallinger S, Le Marchand L, Newcomb PA,Haile RW, Hopper JL, Jenkins MA (2012) Colorectal and other cancerrisks for carriers and noncarriers from families with a DNA mismatchrepair gene mutation: a prospective cohort study. J Clin Oncol 30:958-964